U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809867) titled 'Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis' on Sept. 03.
Brief Summary: The goal of this clinical trial is to support the development of personalized therapy tailored to each patient's individual characteristics. A better understanding of the pharmacokinetic profiles of elexacaftor, tezacaftor, and ivacaftor is essential to support Therapeutic Drug Monitoring (TDM) and to guide dose adjustments when clinically indicated, without compromising therapeutic efficacy.
The study will include male and female patients aged >=6 years with Cystic Fibrosis (CF) carrying at least one F508del mutation and receiving...